A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL.

Trial Details

NCT ID

NCT06043323

Phase

PHASE2

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

Axicabtagene Ciloleucel
Cyclophosphamide
Fludarabine phosphate
Prednisone
Diphenhydramine
Acetaminophen

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Eligible subjects will be considered for inclusion if they meet all of the following criteria:
Men and women 18 years of age or older
Histologically proven FL (Grade 1-3A) on most recent biopsy, history of transformed follicular lymphoma permitted at clinician discretion)
Patients with follicular lymphoma must have disease that has relapsed or is refractory to 2 or more prior lines of systemic therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →